Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSL2109 in Advanced Solid Tumors
NCT07514065Phase 1Recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TSL2109 in solid tumor, prostate cancer (PCa) and breast cancer, sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoint: Tolerability assessment. Started Feb 2026; status: recruiting.
02
Drugs
TSL2109
03
Conditions
solid tumorprostate cancer (PCa)breast cancer
Beyond the preview
Go deeper on NCT07514065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514065.